Skip to main content

Table 1 Clinicopathologic features of the 70 patients classified according to radioiodine (RAI) avidity/refractoriness and disease status

From: The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer

Clinicopathologic features RAI+/D+ (23) RAI−/D+ (32) RAI+/D- (15) P
Age at diagnosis (years), median ± SD 44 ± 20.5 47 ± 18.7 44 ± 16.6 0.81
Female gender, n (%) 16 (70) 21 (66) 10 (67) 0.95
Tumor diagnosis, n (%)
 Incidental 4 (17) 5 (16) 1 (7) 0.62
 Pre-surgical 19 (83) 27 (84) 14 (93)  
Tumor size (mm), median (IQR) 2.3 (0.9–0.6) 2.2 (0.7–4.2) 2.4 (1.2–5) 0.27
Histological variant, n (%)
 CPTC 19 (83) 29 (90) 10 (67) 0.001
 FVPTC 0 3 (10) 5 (33)  
 SCL/COL/TALL/PDTC 2/0/1/1 (9/0/4/4) 0/0/0/0 0/0/0/0  
Extrathyroidal Invasion, n (%)
 Yes 18 (78) 18 (56) 10 (67) 0.23
 No 5 (22) 14 (44) 5 (33)  
Multifocality, n (%)
 Yes 16 (70) 17 (53) 12 (80) 0.16
 No 7 (30) 15 (47) 3 (20)  
TNM, n (%)
  T1 3 (13) 8 (25) 2 (13) 0.28
  T2-T3-T4 20 (87) 24 (75) 13 (87)  
  N0 0 (0) 6 (19) 0 (0) 0.24
  N1 23 (100) 26 (81) 15 (100)  
  M0 18 (78) 25 (78) 15 (100) 0.13
  M1 5 (22) 7 (22) 0  
AJCC stage, n (%)
 I 13 (57) 15 (47) 9 (60) 0.64
 II-III-IV 10 (43) 17 (53) 6 (40)  
ATA risk stratification, n (%)
 Low 0 (0) 0 (0) 0 (0) 0.61
 Intermediate/High 22/1 (96/4) 30/2 (94/6) 15/0 (100/0)  
Cumulative dose of RAI (mCi) median ± SD 85 ± 47.8 76 ± 37.1 75 ± 33.4 0.21
  1. All cases have been submitted to radioiodine ablation after surgery
  2. Legend: RAI radioiodine, RAI- without radioiodine uptake, RAI+ with radioiodine uptake, D disease, D- cured, D+ persistence/relapse, SD Standard Deviation, CPTC Conventional Papillary Thyroid Carcinoma, FVPTC Follicular Variant Papillary Thyroid Carcinoma, SCL Sclerosing Papillary Thyroid Carcinoma, COL Columnar Papillary Thyroid Carcinoma, TALL Tall Cell Papillary Thyroid Carcinoma, PDTC Poorly Differentiated Thyroid Carcinoma